Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $300.00 at Royal Bank of Canada

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target increased by Royal Bank of Canada from $265.00 to $300.00 in a report released on Friday, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued research reports about the stock. Canaccord Genuity Group boosted their price target on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the stock a buy rating in a research note on Friday. TD Cowen boosted their price target on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the stock a buy rating in a research note on Tuesday, June 25th. SVB Leerink boosted their price target on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a market perform rating in a research note on Tuesday, June 25th. Citigroup boosted their price target on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a buy rating in a research note on Friday. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Alnylam Pharmaceuticals from $160.00 to $248.00 and gave the stock a neutral rating in a report on Wednesday, July 3rd. Eight investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of Moderate Buy and an average price target of $269.32.

Alnylam Pharmaceuticals Trading Down 2.6 %

Shares of NASDAQ:ALNY opened at $265.00 on Friday. The company has a 50 day moving average of $211.34 and a 200 day moving average of $175.01. The stock has a market cap of $33.52 billion, a P/E ratio of -98.88 and a beta of 0.37. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $274.93.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to analysts’ expectations of $447.22 million. Alnylam Pharmaceuticals’s revenue was up 107.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.21) EPS. On average, equities analysts forecast that Alnylam Pharmaceuticals will post -3.99 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,301 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $1,917,447.99. Following the completion of the transaction, the chief executive officer now directly owns 80,534 shares in the company, valued at approximately $18,602,548.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,301 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $1,917,447.99. Following the completion of the transaction, the chief executive officer now directly owns 80,534 shares in the company, valued at approximately $18,602,548.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Amy W. Schulman sold 21,700 shares of the company’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the sale, the director now directly owns 8,436 shares in the company, valued at $1,253,589.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 89,598 shares of company stock worth $19,377,944. 1.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ALNY. Raymond James & Associates grew its position in shares of Alnylam Pharmaceuticals by 15.1% in the 4th quarter. Raymond James & Associates now owns 14,286 shares of the biopharmaceutical company’s stock worth $2,734,000 after buying an additional 1,875 shares during the period. Ballentine Partners LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $234,000. Arizona State Retirement System grew its position in shares of Alnylam Pharmaceuticals by 1.1% in the 4th quarter. Arizona State Retirement System now owns 34,356 shares of the biopharmaceutical company’s stock worth $6,576,000 after buying an additional 383 shares during the period. Quilter Plc purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $255,000. Finally, Asset Management One Co. Ltd. grew its position in Alnylam Pharmaceuticals by 41.3% during the 4th quarter. Asset Management One Co. Ltd. now owns 69,334 shares of the biopharmaceutical company’s stock valued at $13,569,000 after purchasing an additional 20,268 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.